Optimizing poly (ADP-ribose) polymerase inhibition through combined epigenetic and immunotherapy

Medicine and Dentistry

• Anticarcinogen 16%
• Breast Cancer 16%
• Cancer 33%
• Cancer Stem Cell 33%
• Cell Population 16%
• DNA Repair 16%
• Genetics 16%
• Histone Deacetylase Inhibitor 33%
• Histone Demethylase 33%
• Homologous Recombination 33%
• Immunogenic Cell Death 16%
• Immunotherapy 100%
• Lysine 33%
• PARP Inhibitor 100%
• Poly ADP Ribose Polymerase 100%
• Programmed Cell Death 50%
• Programmed Death 1 Ligand 1 33%
• Targeted Therapy 16%
• Triple Negative Breast Cancer 33%
• Tumor 16%
• Tumor Progression 16%
• Tumor Recurrence 33%

Immunology and Microbiology

• Cancer Stem Cell 50%
• Cell Death 50%
• Cell Population 25%
• DNA Repair 25%
• Histone 100%
• Homologous Recombination 50%
• Immunotherapy 100%
• Lysine 50%
• Programmed Cell Death 1 50%
• Programmed Death 1 Ligand 1 50%

Biochemistry, Genetics and Molecular Biology

• Anticancer 14%
• Cancer Stem Cell 28%
• Cell Death 57%
• Demethylase 28%
• DNA Repair 14%
• Genetics 14%
• Histone 28%
• Histone Deacetylase 28%
• Homologous Recombination 28%
• Lysine 28%
• Poly ADP Ribose Polymerase 100%
• Programmed Cell Death 1 28%
• Targeted Therapy 14%
• Tumor Progression 14%